Iovance Biotherapeutics shares rise 17.20% premarket after Amtagvi® receives Health Canada approval for advanced melanoma treatment.

Iovance Biotherapeutics, Inc. rose 17.20% in premarket trading, driven by the news that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi® (lifileucel), a tumor-derived autologous T cell immunotherapy. This approval marks the first T cell therapy for a solid tumor cancer and the first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy.